Bedrijfsoverzicht
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to developing novel immunotherapies designed for the treatment of cancer, with a specific focus on pipeline products like BDC-4182 which targets the tumor-associated antigen claudin 18.2 for gastric applications. The company operates within the healthcare sector, specifically inside the biotechnology industry, where it functions as a pre-commercial entity relying on external capital to advance its scientific research rather than generating significant commercial sales. The firm currently maintains a market capitalization of $9.43M and employs a workforce of 23 individuals, reflecting a very small-scale organization typical of early-stage biotech development. These financial dimensions indicate that the company is a micro-cap entity with limited revenue generation capabilities, positioning it as a high-risk, high-potential asset that relies heavily on successful clinical trial outcomes to transition from a research-focused model to a commercially viable pharmaceutical producer.
Financiële gezondheid
Bolt Biotherapeutics reported a total revenue of $7.70M over the trailing twelve months, while recording a net income of $-33,376,000 and an EBITDA of $-33,342,000, revealing a substantial gap between top-line income and profitability. This significant divergence between revenue and net income highlights an aggressive cost structure characterized by high research and development expenditures that far exceed current sales, a common feature in clinical-stage biotechnology firms. The company generated a free cash flow of $-24,904,624, indicating a continuous cash burn that limits immediate financial flexibility and necessitates ongoing access to capital markets or private funding sources. Margin analysis shows a gross margin of -270.8%, an operating margin of -224.2%, and a profit margin of 0.0%, all of which reflect the intense upfront investment required to bring a drug candidate to market before any commercial profit can be realized. On the balance sheet, the company holds $27.50M in cash against $22.96M in debt, resulting in a debt-to-equity ratio of 86.62, which suggests a leveraged position where liabilities are substantial relative to shareholders' equity despite the cash buffer. Liquidity is supported by a current ratio of 3.59, indicating that the company possesses sufficient current assets to cover its short-term obligations with a wide margin of safety. Finally, the return on equity stands at -79.7% and the return on assets at -27.7%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a standard characteristic of companies in the development phase.
Waarderingsbeoordeling
The valuation metrics for Bolt Biotherapeutics present a complex picture, with a P/E ratio (TTM) listed as N/A due to the lack of positive earnings, and a forward P/E of -0.20, which implies that the market expects earnings to remain negative or for the company to continue burning cash in the near term. The price-to-book ratio is recorded at 0.36, indicating that the stock trades at a significant discount to its book value, a scenario often observed in biotech firms where the value of intellectual property and future pipeline potential is not fully captured on the current balance sheet. Alternative valuation measures include a price-to-sales ratio of 1.23 and an EV/EBITDA of -0.15, suggesting that investors are pricing the company based on its sales generation potential rather than current profitability or discounted cash flows. Regarding trading range, the stock has a 52-week high of $9.24 and a 52-week low of $3.91, meaning the current price sits within a volatile band where the forward P/E metric alone cannot serve as a traditional valuation anchor. The company exhibits a beta of 0.86, which indicates that its price volatility is slightly lower than the broader market, suggesting that while the stock is subject to general market movements, it does not amplify market swings as aggressively as high-beta technology or financial stocks.
Growth & Income
The available data lists revenue growth (YoY) and earnings growth (YoY) as N/A, which reflects the typical situation for a company with a short trading history or irregular reporting cycles common in the biotech sector. Since the company is not a dividend payer, there is no dividend yield or payout ratio to analyze, as the payout ratio is effectively 0.0% because all available earnings are retained or, more accurately, the company reinvests its limited resources directly into clinical trials and operational expansion rather than distributing income to shareholders. This reinvestment strategy is essential for clinical-stage biopharmaceutical firms that must allocate capital to advance their pipeline from preclinical discovery through to clinical trials to eventually achieve commercialization. Consequently, the overall growth and income profile for Bolt Biotherapeutics is defined by a lack of current income distribution and an absence of historical growth data, relying entirely on future clinical success and regulatory approval to drive future revenue expansion and potential profitability.